Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Ono Enters into License Agreement with Bial

Published: Tuesday, April 30, 2013
Last Updated: Tuesday, April 30, 2013
Bookmark and Share
Ono Pharmaceutical Co., Ltd. announced that the company has obtained the right to exclusively develop and commercialize BIA 9-1067.

BIA 9-1067 (development code) (generic name: Opicapone) in Japan, is a long acting COMT (Cathechol-O-Methyl Transferase) inhibitor originated by and currently being developed outside Japan by Bial (Porto, Portugal, CEO: António Portela) for the treatment of symptom reemergence due to levodopa “wearing-off” in Parkinson’s disease (PD).

Under the License Agreement, Ono will pay Bial an upfront fee and development and sales milestones based on the development stage and sales performance of Opicapone.

Opicapone is an adjunct therapy to levodopa preparations (levodopa/carbidopa or levodopa/benserazide) in PD patients. It is well established that levodopa preparations offer the most effective symptomatic treatment of PD. As the disease progresses, PD patients develop “wearing off” phenomenon, where the duration of the effect of levodopa is shortened. To address this “wearing off” phenomenon, adjunctive therapy to levodopa preparations is used to help maintain or boost the effects of levodopa. COMT inhibitors have been widely used to prolong the duration of levodopa effect.

The existing COMT inhibitor in Japan requires multiple administration per day due to its short duration of action and is concomitantly administered with each levodopa preparation.

Phase 3 clinical studies of Opicapone by BIAL are currently ongoing and in clinical studies so far it has demonstrated an increase in the systemic exposure to levodopa and showed a long-lasting effect on COMT inhibition from once daily dosing. Opicapone is expected to improve a dosing convenience, compared to the existing COMT inhibitor in Japan.

Ono will continue to make great efforts to offer a new drug which truly contributes to patients wellbeing and fulfills unmet medical needs.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Electronic Reminders Keep TB Patients on Track With Medication In China
Giving electronic reminders to tuberculosis (TB) patients in China can reduce the amount of medication doses they miss by half, according to new research.
Common Drug Presents Fracture Risk To Older Women
Researchers are urging caution in prescribing one of the world’s most commonly issued drug groups, citing links to increased fracture risks in older Australian women.
Combining Epigenetic Therapies and Immunotherapies Improves Cancer Outcomes
Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs.
LiMAx Test Shows Reversibility of Fatty Liver Disease After Obesity Surgery
Clinical study provides evidence for functional liver recovery after weight loss.
Landmark NIH Study Shows Intensive Blood Pressure Management May Save Lives
Lower blood pressure target greatly reduces cardiovascular complications and deaths in older adults.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos